Allianz SE Buys 5,080 Shares of BioNTech SE Sponsored ADR $BNTX

Allianz SE grew its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 635.0% in the second quarter, according to its most recent filing with the SEC. The fund owned 5,880 shares of the company’s stock after acquiring an additional 5,080 shares during the period. Allianz SE’s holdings in BioNTech were worth $626,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Banque Cantonale Vaudoise acquired a new position in BioNTech in the 1st quarter worth about $36,000. LRI Investments LLC boosted its stake in shares of BioNTech by 234.6% during the second quarter. LRI Investments LLC now owns 445 shares of the company’s stock valued at $47,000 after purchasing an additional 312 shares in the last quarter. Hantz Financial Services Inc. grew its holdings in shares of BioNTech by 472.0% during the second quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock worth $61,000 after purchasing an additional 472 shares during the last quarter. Banque Transatlantique SA acquired a new position in shares of BioNTech in the first quarter valued at approximately $80,000. Finally, Costello Asset Management INC bought a new position in BioNTech in the 1st quarter valued at approximately $91,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Trading Down 7.0%

NASDAQ BNTX opened at $103.88 on Friday. The stock has a market capitalization of $24.98 billion, a P/E ratio of -64.92 and a beta of 1.54. The business has a 50 day simple moving average of $103.10 and a 200 day simple moving average of $104.95. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48. BioNTech SE Sponsored ADR has a one year low of $81.20 and a one year high of $129.27.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.75 by ($0.89). The business had revenue of $1.78 billion during the quarter, compared to analyst estimates of $1.21 billion. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. BioNTech’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same period last year, the firm posted $0.81 earnings per share. BioNTech has set its FY 2025 guidance at EPS. Research analysts expect that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

BNTX has been the topic of a number of research reports. Wells Fargo & Company set a $150.00 target price on shares of BioNTech and gave the stock an “overweight” rating in a report on Tuesday, August 5th. HC Wainwright lifted their price target on shares of BioNTech from $136.00 to $140.00 and gave the stock a “buy” rating in a report on Monday. Jefferies Financial Group restated a “buy” rating on shares of BioNTech in a report on Wednesday. Cowen reaffirmed a “hold” rating on shares of BioNTech in a research report on Monday, November 3rd. Finally, Bank of America reduced their price target on BioNTech from $134.00 to $130.00 and set a “buy” rating on the stock in a research report on Wednesday, October 22nd. Eleven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and a consensus price target of $134.10.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.